[5] Druker helped develop imatinib (Gleevec), the first medication that specifically targets cancer cells, for the treatment of chronic myeloid leukemia (CML).

[6][8][7] This work changed the life expectancy of patients with CML from an average of 3 to 5 years to a 89% five-year survival,[20][21] and has resulted in a paradigm-shift in cancer treatment from non-specific chemotherapy to highly targeted therapeutic agents.

[22] Druker has been widely recognized for his work in developing Gleevec, but has been publicly critical of the drug's high price for patients.

[23][24] Druker also helped lead a national clinical trial to find effective treatments for acute myeloid leukemia (AML).

[28] Druker abruptly resigned in December 2024 while "looking for opportunities where (he) can continue to make an impact on patient’s lives and on the world.

"[29] He continues to lead his research lab and see patients, but has expressed strong criticism of OHSU, stating that the institution has "lost sight of what is crucial and forgotten (its) mission.